Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two ...

LTI-03 is formulated as a dry powder inhalation therapy that's designed to help ease fibrosis and symptoms of idiopathic ...

Columnist Sam Kirton pays tribute to his friend and IPF mentor, Pieter van den Assum, who passed away on May 17.

GRI Bio has reached an interim enrollment goal for its Phase 2a clinical trial testing GRI-0621 — a therapy targeting natural killer T-cells (NKT cells) to treat idiopathic pulmonary fibrosis (IPF) — ...

Leave no stone unturned. This is a basic tenet of any investigation, something I learned very early in my career as a special agent. It also seems to be a practice employed by my healthcare team, ...

A committee of the European Medicines Agency (EMA) is recommending orphan drug status — a designation that aims to speed therapy development in rare diseases — for tranilast, the active ingredient in ...

Pulmonary fibrosis (PF) is a respiratory condition that causes the formation of scar tissue in the lungs. It is progressive disease and can take years to progress. Because of thickening lung tissue, ...

Disrupting the rhythm of day-to-day life with pulmonary fibrosis comes at a cost. My pretransplant medications can be best described as a primer for what was to come. Following my bilateral lung ...

Pulmonary fibrosis (PF) is characterized by scarring, or fibrosis, in the lungs. Scar tissue development can interfere with the lungs’ ability to deliver oxygen to the bloodstream, as well as with ...

According to the National Institutes of Health (NIH), about 100,000 people in the U.S. have pulmonary fibrosis. Between 30,000 and 40,000 new cases are diagnosed every year. While inherited pulmonary ...